Dyslipidemia
Conditions
Brief summary
Total (first and subsequent) composite of myocardial infarction, ischemic stroke, any arterial revascularization procedure, and all-cause death.
Detailed description
Percent LDL-C change from baseline to 12 weeks and 52 week in a subset of approximately 300 selected subjects., Total (first and subsequent) composite of myocardial infarction, ischemic stroke, any arterial revascularization procedure, and cardiovascular death., Time to the first occurrence of the composite of myocardial infarction, ischemic stroke, revascularization procedure, and all-cause death., Total myocardial infarctions, Total arterial revascularization procedures, Total ischemia-driven coronary revascularization procedures, Total ischemic strokes, Cardiovascular death, All-cause death
Interventions
DRUGEVOLOCUMAB
Sponsors
Amgen Inc.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total (first and subsequent) composite of myocardial infarction, ischemic stroke, any arterial revascularization procedure, and all-cause death. | — |
Secondary
| Measure | Time frame |
|---|---|
| Percent LDL-C change from baseline to 12 weeks and 52 week in a subset of approximately 300 selected subjects., Total (first and subsequent) composite of myocardial infarction, ischemic stroke, any arterial revascularization procedure, and cardiovascular death., Time to the first occurrence of the composite of myocardial infarction, ischemic stroke, revascularization procedure, and all-cause death., Total myocardial infarctions, Total arterial revascularization procedures, Total ischemia-driven coronary revascularization procedures, Total ischemic strokes, Cardiovascular death, All-cause death | — |
Countries
Sweden
Outcome results
None listed